prikaz prve stranice dokumenta Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi
  Download
PDF 702.88 KB
master's thesis
Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi
Zagreb: University of Zagreb, School of Medicine, 2017. urn:nbn:hr:105:641928
Kovačić, Matea
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kovačić, M. (2017). Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:641928

Kovačić, Matea. "Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:641928

Kovačić, Matea. "Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi." Master's thesis, University of Zagreb, School of Medicine, 2017. https://urn.nsk.hr/urn:nbn:hr:105:641928

Kovačić, M. (2017). 'Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi', Master's thesis, University of Zagreb, School of Medicine, accessed 27 December 2024, https://urn.nsk.hr/urn:nbn:hr:105:641928

Kovačić M. Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2017 [cited 2024 December 27] Available at: https://urn.nsk.hr/urn:nbn:hr:105:641928

M. Kovačić, "Duboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2017. Available at: https://urn.nsk.hr/urn:nbn:hr:105:641928

Metadata
TitleDuboka venska tromboza kod bolesnika s kroničnom bubrežnom bolesti i direktni oralni antikoagulantni lijekovi
Title (english)Deep venous thrombosis in patients with chronic kidney disease and direct oral anticoagulants
AuthorMatea Kovačić
MentorIngrid Prkačin (mentor)
Committee memberIvan Gornik (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberIngrid Prkačin (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2017-07-14, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Pharmacology
Abstract
Duboka venska tromboza je multifaktorijalna i česta bolest, pogotovo kod starijih ljudi. Prepoznati su brojni čimbenici rizika za njen nastanak. Pacijenti s kroničnom bubrežnom bolesti predstavljaju specifičnu skupinu. Oni su visokorizična skupina za trombozu, kako u venskoj, tako i u arterijskoj cirkulaciji. Osim toga, zbog poremećaja u građi membrane trombocita imaju povećan rizik od krvarenja. Direktni oralni antikoagulantni lijekovi (DOAK) su odobreni u liječenju više tromboembolijskih stanja i imaju prednosti pred tradicionalnom terapijom. Postali su lijekovi prvog izbora za liječenje venske tromboembolije. Četiri DOAK-a, uključujući tri inhibitora faktora Xa (rivaroksaban, apiksaban i edoksaban) i jedan inhibitor trombina (dabigatran), predstavljaju terapijsku alternativu antagonistima vitamina K. U usporedbi s varfarinom, DOAK-i imaju širi terapijski raspon, ne zahtijevaju rutinsko laboratorijsko praćenje učinka i ne ulaze u interakcije s hranom. Nažalost, postoji vrlo malo podataka o upotrebi DOAK-a kod pacijenata s teško oštećenom bubrežnom funkcijom. Svaki se DOAK dijelom izlučuje bubrezima. Iz tog razloga pacijentima treba periodično procjenjivati bubrežnu funkciju kako bi se utvrdilo je li lijek kontraindiciran i kako bi se, što je rijetko potrebno, prilagodila doza.
Abstract (english)
Deep venous thrombosis is a multifactorial and common disease, especially in the elderly. A number of risk factors for thrombosis have been identified. Patients with chronic kidney disease represent a special group. They represent a high-risk group for thrombosis both in the cardiovascular territory and also in the venous circulation. On the other hand, abnormalities in the platelet membranes put them at higher risk of bleeding. Direct oral anticoagulants (DOAC) are approved for multiple thromboembolic disorders and provide advantages over existing agents. They have now become the first-line choice for treatment of venous thromboembolism. The four DOACs, including the three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and one direct thrombin inhibitor (dabigatran), provide oral anticoagulation therapy alternatives to vitamin K antagonist therapy. Compared with warfarin, the DOACs have a wider therapeutic index, not requiring routine laboratory monitoring or dietary restrictions. Unfortunately, extremely limited data exist for the use of DOACs in patients with severe renal insufficiency. Each of the DOACs is, at least in part, cleared by the kidneys. For that reason, the patients require periodic assessment of renal function to determine when dose adjustments are necessary or if their use is contraindicated.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:641928
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-04-03 11:32:41